Monoclonal antibodies to the interleukin­-6 receptor in the treatment of COVID-­19 in patients with chronic kidney disease

Abstract

Interleukin­-6 (IL-­6) plays a key role in the pathogenesis of COVID­19, which determines the indications for the therapeutic use of its antagonists. However, data on their effectiveness and optimal timing of appointment are contradictory. The question of the possibility of their use in patients with impaired kidney function has not been studied.

The aim of the study is to evaluate the efficacy and safety of the use of monoclonal antibodies to IL-­6 receptors in COVID-­19 in patients with chronic kidney disease (CKD) of stages 2–5 (predialysis) who do not need renal replacement therapy.

Material and methods. A clinical retrospective uncontrolled single­center study included 45 patients (60% of men) with CKD stages 2–5 aged 22–95 years (median – 58 years) hospitalized with predominantly severe uncritical COVID­-19 infection. Treatment of COVID-­19 was carried out in accordance with the Interim guidelines for the prevention and treatment of new coronavirus infection of the Ministry of Health of Russian Federation.

Results. The majority of patients (n=36; 73.3%) had CKD stage 3b–5, CKD stage 2 was in 7 (15.5%) and stage 3a – in 5 (11.1%) patients. The median serum creatinine level (Cr) was 164 [131; 292] µmol/l, glomerular filtration rate (GFR) was 30 [13; 49] ml/min/1.73 m2, CRP 67.5 [37.2; 106.75] mg/l. The introduction of monoclonal antibody to IL-­6 receptors led to a decrease in the activity of the infectious process (CRP 1.55 [0.33; 4.15] mg/l, p<0.001), regression of pneumonia, which did not require mechanical ventilation and hospitalization in the intensive care unit. According to the decision of the medical commission, patients were injected with monoclonal antibodies to IL-­6 receptors: tocilizumab (n=36; 80%), levilimab (n=2; 4.4%), combined therapy with two drugs (n=7; 15.5%). Therapy with IL­-6 antagonists did not have a negative effect on kidney function. The levels of Cr decreased on average from 224.3±145.2 mmol/l at admission to 160±92.55 mmol/l at discharge (p<0.001), GFR increased from 32.6±20.9 ml/min/1.73 m2 at admission to 53±31.7 ml/min/1.73 m2 at discharge (p<0.001). In the majority of patients (n=36, 80%) GFR has risen, and only in 9 (20%) cases it remained approximately at the same low level. No serious adverse events have been reported with the use of IL-­6 antagonists, as well as concomitant infectious complications. No deaths have been reported. The median length of stay in bed was 14 [10; 19] days.

Conclusion. The results of the study allow us to state that in patients with CKD, monoclonal antibodies to IL-­6 receptors have a good safety profile and can be successfully used in moderate and severe forms of COVID­-19, regardless of the state of kidney function.

Keywords:COVID-19; monoclonal antibodies to the IL-6 receptor; tocilizumab; chronic kidney disease; impaired kidney function

Funding. The study had no financial support.

Conflict of interest. The authors declare no conflict of interest.

Contribution. Research concept and design – Tomilina N.A., Frolova N.F.; collection and processing of material – Usatiuk S.S., Artyukhina L.Yu., Diakova E.N., Mayorov V.V., Sysoyeva I.L.; statistical data processing – Stolyarevich E.S., Kim I.G.; text writing – Tomilina N.A., Frolova N.F., Volgina G.V.; editing – Tomilina N.A., Frolova N.F., Volgina G.V.; approval of the final version of the article – Tomilina N.A., Volgina G.V.

For citation: Frolova N.F., Tomilina N.A., Usatiuk S.S., Artyukhina L.Yu., Diakova E.N., Mayorov V.V., Sysoyeva I.L., Stolyarevich E.S., Kim I.G., Volgina G.V. Monoclonal antibodies to the interleukin­6 receptor in the treatment of COVID-­19 in patients with chronic kidney disease. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2022; 11 (1): 77–84. DOI: https://doi.org/10.33029/2305-3496-2022-11-1-77-84

References

1. Huang C., Wang Y., Li X., Ren L. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. 2020. Vol. 395, N 10223. P. 497–506.

2. Johns Hopkins University of Medicine Coronavirus Resource Center. Data in Motion. 27.06.2021.

3. Wu Z., McGoogan J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention // JAMA. 2020. Vol. 323, N 13. P. 1239–1242. DOI: https://doi.org/10.1001/jama.2020.2648.

4. Yang X., Yu Y., Xu J., Shu H. et al Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study // Lancet Respir. Med. 2020. Vol 8, N 5. P. 475–481. DOI: https://doi.org/10.1016/S2213-2600(20)30079-5

5. Horby P., Lim S., Emberson J.R. et al Dexamethasone in hospitalized patients with Covid-19 – Preliminary Report. The RECOVERY Collaborative Group // N. Engl. J. Med. 2021.Vol. 384, N 8. P. 693–704. DOI: https://doi.org/10.1056/NEJMoa2021436

6. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet. 2020. Vol. 395, N 10229. P. 1054–1062. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3

7. Carsana L., Sonzogni A., Nasr A. et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy:a two-centre descriptive study // Lancet Infect. Dis. 2020. Vol. 20, N 10. P. 1135–1140. DOI: https://doi.org/10.1016/S1473-3099(20)30434-5

8. Wong C.K., Lam C.W.K., Wu A.K.L. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome // Clin. Exp. Immunol. 2004. Vol. 136, N 1. P. 95–103. DOI: https://doi.org/10.1111/j.1365-2249.2004.02415.x

9. Baillie J.K., Digard P. Influenza – time to target the host? // N. Engl. J. Med. 2013. Vol. 369, N 2. P. 191–193. DOI: 10.1056/NEJMcibr1304414

10. Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19 // Science. 2020. Vol. 368, N 6490. P. 473–474. DOI: https://doi.org/10.1126/science.abb8925

11. Gupta S., Leaf D.E. Tocilizumab in COVID-19: some clarity amid controversy // Lancet. 2021.Vol. 397, N 10285. P. 1599–1601. DOI: https://doi.org/10.1016/S0140-6736(21)00712-1

12. Ruan Q., Yang K., Wang W. et al. Clinical predictors of mortality due to COVID‑19 based on an analysis of data of 150 patients from Wuhan, China // Intensive Care Med. 2020. Vol. 46, N 5. P. 846–848. DOI: https://doi.org/10.1007/s00134-020-05991-x

13. Временные методические рекомендации. “Профилактика и лечение новой коронавирусной инфекции (COVID-19).” Версия 11 (от 07.05.2021). Москва : Министерство здравоохранения Российской Федерации, 2021.

14. Rochwerg B., Siemieniuk R.A., Agoritsas T. еt al. Corticosteroids for COVID-19 Practice guideline // BMJ. 2020. Vol. 370. P. m3379. DOI: https://doi.org/10.1136/bmj.m3379

15. Tanaka T., Narazaki M., Kishimoto T., IL-6 in inflammation, immunity, and disease // Cold Spring Harb. Perspect Biol. 2014. Vol 6, N 10. P. 1–16. DOI: https://doi.org/10.1101/cshperspect.a016295

16. Kang S., Narazaki M., Metwally H., Kishimoto T. Historical overview of the interleukin-6 family cytokine // J. Exp. Med. 2020. Vol. 217, N 5. P. 1–10. DOI: https://doi.org/10.1084/jem.20190347

17. Murakami M., Kamimura D., Hirano T. Pleiotropy and specificity: insights from the interleukin 6 family of cytokines // Immunity 2019. Vol. 50, N 4. P. 812–823. DOI: https://doi.org/10.1016/j.immuni.2019.03.027

18. Samaee H., Mohsenzadegan M., Ala S. et al. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease // Int. Immunopharmacol. 2020. Vol. 89, PT A. 107018. DOI: https://doi.org/10.1016/j.intimp.2020.107018

19. Временные методические рекомендации. “Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)”: версия 9 (от 26.10.2020). Москва : Министерство здравоохранения Российской Федерации, 2020.

20. Kaplon H., Reichert J.M. Antibodies to watch in 2021 // Mabs. 2021. Vol. 13, N 1. 1860476. DOI: https://doi.org/10.1080/19420862.2020.1860476

21.Ghosn L., Chaimani A., Evrenoglou T. et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Meta-Analysis // Cochrane Database Syst. Rev. 2021. Vol. 3, CD013881. DOI: 10.1002/14651858.CD013881

22. Parr J.B. Time to reassess tocilizumab’s role in COVID-19 pneumonia // JAMA Intern. Med. 2021. Vol. 181, N 1. P 12–15. DOI: https://doi.org/10.1001/jamainternmed.2020.6557

23. Xu X., Han M., Li T. et al. Effective treatment of severe COVID-19 patients with tocilizumab // Nat. Acad. Sci. USA. 2020. Vol. 117, N 20. P. 10970–10975. DOI: https://doi.org/10.1073/pnas.2005615117

24. Luo P., Liu Y., Qiu L. et al Tocilizumab treatment in COVID-19: A single center experience // J. Med. Virol. 2020. Vol. 92, N 7. P. 814–818. DOI: https://doi.org/10.1002/jmv.25801

25. Guaraldi G., Meschiari M., Cozzi-Lepri A. et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study // Lancet Rheumatol. 2020. Vol. 2, N 8. P. e474–e484. DOI: https://doi.org/10.1016/S2665-9913(20)30173-9

26. Somers E.C., Eschenauer G.A., Troost J.P. et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19 // Clin. Infect. Dis. 2020. Ciaa954. DOI: https://doi.org/10.1093/cid/ciaa954. Online ahead of print.

27. Biran N., Ip A., Ahn J. et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicenter observational study // Lancet Rheumatol. 2020. Vol. 2, N 10. P. e603–e612. DOI: https://doi.org/10.1016/S2665-9913(20)30277-0

28.  Hermine O., Mariette X., Tharaux P-L. et al. for the CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized clinical trial // JAMA Intern. Med. 2021. Vol. 181, N 1. P. 32–40. DOI: https://doi.org/10.1001/jamainternmed.2020.6820

29. Gupta S., Wang W., Hayek S.S. et al. Association between early treatment with tocilizumab and mortality among critically ill patients with covid-19 // JAMA Intern. Med. 2021. Vol. 181, N 1. P. 41–51. DOI: https://doi.org/10.1001/jamainternmed.2020.6252

30.REMAP-CAP Investigators; Gordon A. C., Mouncey P.R., Al-Beidh F. et al. Interleukin-6 receptor antagonists in critically ill patients with covid-19 // N. Engl. J. Med. 2021. Vol. 384, N 16. P. 1491–1502. DOI: https://doi.org/10.1056/NEJMoa2100433

31. Alberici F., Delbarba E., Manenti C. et al. Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy. // Kidney Int. Rep. 2020. Vol. 5, N 5. P. 580–585. DOI.org/10.1016/j.ekir.2020.04.001

32. Trujillo H., Caravaca-Fontán F., Sevillano Á. et al. Tocilizumab use in kidney transplant patients with COVID-19 // Clin. Transplant. 2020. Vol. 34, N 11. E14072. DOI: https://doi.org/10.1111/ctr.14072

33. Pérez-Sáez M.J., Blasco M., Redondo-Pachón D. et al. Use of tocilizumab in kidney transplant recipients with COVID-19 // Am. J. Transplant. 2020. Vol. 20, N 11. P. 3182–3190. DOI: https://doi.org/10.1111/ajt.16192

34. Ким И.Г., Артюхина Л.Ю., Фролова Н.Ф. и др. SARS-CoV-2 инфекция у реципиентов почечного трансплантата // Нефрология и диализ. 2021. Т. 23, № 2. C. 174–184. DOI: https://doi.org/10.28996/2618-9801-2021-2-174-184

35. Фролова Н.Ф., Ким И.Г., Ушакова А.И. и др. COVID-19 у больных, получающих лечение программным гемодиализом // Инфекционные болезни: новости, мнения, обучение. 2021. Т. 10, № 1. С. 14–23. DOI: https://doi.org/10.33029/2305-3496-2021-10-1-14-23

36. Временные методические рекомендации. «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 8 (от 03.09.2020). Москва : Министерство здравоохранения Российской Федерации, 2020.

37. Levey A.S., Stevens L.A. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions // Am. J. Kidney Dis. 2010. Vol. 55, N 4. P. 622–627. DOI: https://doi.org/10.1053/j.ajkd.2010.02.337

38.Salvarani C., Dolci G., Massari M. et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial // JAMA Intern. Med. 2021. Vol. 181, N 1. P. 24–31. DOI: https://doi.org/10.1001/jamainternmed.2020.6615

39.Stone J.H., Frigault M.J., Serling‑Boyd N.J. et al Efficacy of tocilizumab in patients hospitalized with Covid-19 // N. Engl. J. Med. 2020. Vol. 383, N 24. P. 2333–2344. DOI: https://doi.org/10.1056/NEJMoa2028836

40.Ng J.H., Bijol V., Sparks M.A. et al. Pathophysiology and pathology of acute kidney injury in patients with COVID-19 // Adv. Chronic Kidney Dis. 2020. Vol. 27, N 5. P. 365–376. DOI: https://doi.org/10.1053/j.ackd.2020.09.003

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»